The good news is they only need to sell about 20% of the shares they bought at $0.86 to get their initial investment back and can free ride on the rest. The NIH trial should put a floor in there somewhere and taxpayer is paying the trial costs so it is a double free ride. There will be plenty of up volume on uplist to sell that 17 or 2o million or so shares into.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.